Burlingame, CA, United States
Burlingame, CA, United States

Time filter

Source Type

CASTRES, Frankrijk--(BUSINESS WIRE)--Pierre Fabre, de op één na grootste Franse particuliere farmaceutische groep, heeft vandaag de ondertekening van een definitieve koopovereenkomst aangekondigd om diverse activa te verwerven van het biotechnologisch bedrijf Igenica Biotherapeutics, gevestigd in Burlingame, Californië, Verenigde Staten. De overeenkomst omvat innovatieve immunotherapieën die gericht zijn op immuniteitscontrolepunten die de resistentie tegen bestaande immunotherapieën kunnen keren. Het meest geavanceerde actief is momenteel in een preklinische fase en wordt naar verwachting in de komende 2 tot 3 jaar toegediend aan patiënten. De overeenkomst omvat ook een reeks vroegtijdige ontdekkingsdoelstellingen. “Deze overeenkomst is in lijn met recente samenwerkingen ondertekend door Pierre Fabre met biotechnologiebedrijven en academische laboratoria op het gebied van oncologie en dermatologie en bevestigt onze Research & Development-dynamiek via externe partners” aldus Laurent Audoly, hoofd van Pierre Fabre Pharmaceuticals R&D. Over Igenica Biotherapeutics Igenica Biotherapeutics is gericht op de ontdekking en ontwikkeling van antilichamen op het gebied van immuun-oncologie en antilichaam-drugconjugaten (ADC's) voor de behandeling van kanker. Dit bedrijf ondersteunt het spectrum van ADC-ontwikkeling volledig, van een klinisch relevante benadering ten aanzien van het doel en de ontdekking van functionele antilichamen, tot de creatie van ADC's, wat de ontwikkeling en de levering van effectieve therapieën aan patiënten versnelt. Robert Schreiber, Ph.D* was in 2009 mede-oprichter van Igenica. Het bedrijf wordt geleid door een bewezen team van leiders die succes hebben getoond op het gebied van de ontdekking van antilichamen, klinische ontwikkeling en commercialisering. *(Bijzonder hoogleraar Pathologie en Immunologie, hoogleraar Moleculaire Microbiologie, Washington University School of Medicine) Over Pierre Fabre Pierre Fabre is een Frans particulier farmaceutisch en dermo-cosmeticabedrijf dat in 1962 opgericht werd door dhr. Pierre Fabre. De omzet van het bedrijf bedroeg ruim 2,28 miljard euro in 2016, verspreid over 130 landen. Het bedrijf is gestructureerd rond twee divisies: Farmaceutische producten (voorgeschreven medicijnen, consumentengezondheidszorg) en Dermo-cosmetica (waaronder het in Europa en Azië toonaangevende merk Eau Thermale Avène). Pierre Fabre heeft wereldwijd ongeveer 13.000 mensen in dienst en heeft dohterondernemingen in 47 landen. In 2016 wees het bedrijf 14% van de farmaceutische verkoop toe aan R&D, met een focus op 4 therapeutische gebieden: oncologie, dermatologie, CNS en consumentengezondheidszorg. Via de controlerende onderneming Pierre Fabre Participations van de groep is Pierre Fabre voor 86% in handen van de Pierre Fabre Foundation, een sinds 1999 erkende organisatie van openbaar belang. Tot 8,2% van de resterende aandelen zijn in handen van de werknemers van de onderneming en het resterende saldo wordt gehouden als ingekochte eigen aandelen. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.


CASTRES, France--(BUSINESS WIRE)--Pierre Fabre, the 2nd largest French private Pharmaceutical group, today announced the signature of a definitive purchase agreement to acquire several assets from the biotechnology company Igenica Biotherapeutics, based in Burlingame, California, USA. The agreement includes innovative immunotherapies targeting immune checkpoints that may reverse the resistance to existing immuno therapies. The most advanced asset is currently at preclinical stage and is expected to be administered to patients in the coming 2 to 3 years. The agreement also comprises a series of early discovery targets. “This agreement is in line with recent collaborations signed by Pierre Fabre with biotechnology companies and academic laboratories in the fields of oncology and dermatology and confirms our Research & Development dynamic through external partners” said Laurent Audoly, Head of Pierre Fabre Pharmaceuticals R&D. Frédéric Duchesne, Pharmaceutical Division Chief Executive Officer at Pierre Fabre added, “Pierre Fabre’s know-how in oncology is based on more than 30 years of experience. We have two recognized research and development centers with dedicated teams that work closely together to developing medicines for patients living with cancer. This new deal reinforces our position to participate in the revolution of targeted biotherapies and reinforce our commitment to bring substantial value to patients”. Under the terms of the agreement, Pierre Fabre has acquired the full property of the assets. The financial terms of the agreement are not disclosed. “We are very pleased that Pierre Fabre will clinically develop Igenica’s most advanced immune oncology asset for patients suffering from cancer ”said Edward van der Horst, Senior Director of Igenica’s Preclinical Drug Development. About Igenica Biotherapeutics Igenica Biotherapeutics is focused on the discovery and development of antibodies in the field of immune-oncology and antibody-drug conjugates (ADCs) for the treatment of cancer. This company fully powers the ADC development spectrum from a clinically relevant approach to target and functional antibody discovery to ADC creation, accelerating development and the delivery of effective therapies to patients. Co-founded in 2009 by Robert Schreiber, Ph.D*. Igenica is led by a proven team of leaders that have demonstrated success in antibody drug discovery, clinical development and commercialization. *(Alumni endowed Professor of Pathology and Immunology, Professor of Molecular Microbiology, Washington University School of Medicine) About Pierre Fabre Pierre Fabre is a French private pharmaceuticals and dermo-cosmetics company founded in 1962 by Mr. Pierre Fabre. Its turnover reached over 2.28 billion Euros in 2016, spread over 130 countries. The company is structured around two divisions: Pharmaceuticals (prescription drugs, consumer health care) and Dermo-cosmetics (including the Europe and Asia market-leader Eau Thermale Avène brand). Pierre Fabre employs some 13,000 people worldwide and owns subsidiaries in 47 countries. In 2016, the company allocated 14% of its pharmaceuticals sales to R&D with a focus on 4 therapeutic areas: oncology, dermatology, CNS and consumer health care. Pierre Fabre Laboratories have always developed durable and valuable scientific partnerships with innovators from public research institutions (CRNS, Inserm...), faculties and universities (Ecole Polytechnique de Lausanne, Université de Saclay...), international pharmaceutical laboratories (Allergan, Abbvie, Maruho...) and biotech companies (Array BioPharma, AbCheck, Cellectar...). Through the Group’s controlling company Pierre Fabre Participations, Pierre Fabre is 86% owned by the Pierre Fabre Foundation, a recognized public-interest organization since 1999. Up to 8.2% of the remaining shares are held by the company’s employees and the remaining balance is held as treasury stock. To find out more about Pierre Fabre, please go to www.pierre-fabre.com


Patent
Igenica Inc. | Date: 2013-10-09

The invention provides antibodies that bind C16orf54, including antibody-drug conjugates comprising the antibodies, and methods of use of the antibodies and the antibody-drug conjugates, including for the diagnosis and treatment of cancers.


Patent
Igenica Inc. | Date: 2014-06-06

Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 215.74K | Year: 2014

DESCRIPTION (provided by applicant): Antibody drug conjugates (ADCs), a rapidly growing class of targeted therapeutics, represent a promising new approach toward improving both the selectivity and the cytotoxic activity of cancer drugs. Although several ADCs have demonstrated recent clinical success, the utility of most ADCs currently in development is limited by cumbersome synthetic processes, insufficient anti-tumor activity, and unpredictable toxicity. We believe that these drawbacks can be addressed byimprovements in both linker technology and the cytotoxic drugs used to construct the ADCs. Our broad long-term goal is to develop novel ADCs with improved potency, homogeneity and stability over existing targeted therapeutics. Igenica has developed two proprietary technology platforms that provide a complementary function-oriented screening strategy to systematically identify novel tumor associated antigen targets and antigen-specific monoclonal antibodies for constructing ADCs with improved pharmacolo


Provided herein are modified antibodies, compounds used to make them, and intermediates in their synthesis; compositions; formulations and methods, including methods of treating diseases, disorders or conditions, for example, cancer, in humans.


Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.


Antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, tubulysin analogs, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.


Provided herein are antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers


Patent
Igenica Inc. | Date: 2014-06-06

The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.

Loading Igenica Inc. collaborators
Loading Igenica Inc. collaborators